Northwest Biotherapeutics Inc represents a commitment to advancing personalized immunotherapy treatments for cancer patients. The company's corporate philosophy revolves around harnessing the power of the immune system to combat various types of cancer. With a focus on developing innovative therapies, Northwest Biotherapeutics seeks to provide effective and safe treatment options for patients in need. By leveraging its expertise in dendritic cell-based immunotherapy, the company aims to improve survival rates and enhance the quality of life for individuals fighting cancer. Northwest Biotherapeutics Inc prioritizes patient-centric approaches and continues to strive for groundbreaking advancements in the field of cancer immunotherapy.

Northwest Biotherapeutics Inc is primarily present in the United States.

Northwest Biotherapeutics Inc has achieved several significant milestones. Firstly, the company successfully completed Phase III clinical trials for their DCVax®-L product, a personalized immunotherapy treatment for patients with newly diagnosed glioblastoma multiforme (GBM). Additionally, Northwest Biotherapeutics Inc secured orphan drug designation from the FDA for DCVax®-L, providing exclusive market rights and various incentives. Furthermore, the company expanded its manufacturing facility to accommodate increased production capacity, strengthening their market position. Northwest Biotherapeutics Inc's achievements demonstrate their commitment to advancements in personalized immunotherapy treatments, making them a prominent player in the biotechnology industry.

Northwest Biotherapeutics Inc, founded in 1996, is a biotechnology company dedicated to developing personalized immunotherapy treatments for cancer. Headquartered in Bethesda, Maryland, the company specializes in harnessing the body's own immune system to target and destroy tumor cells. Northwest Biotherapeutics Inc has a deep-rooted history in clinical research and innovation, with a focus on developing novel therapies to improve cancer patients' outcomes. With a team of experienced scientists and clinicians, the company has successfully conducted numerous clinical trials, paving the way for potential breakthroughs in cancer treatment. Northwest Biotherapeutics Inc continues to strive towards revolutionizing cancer care through its cutting-edge research and development initiatives.

Northwest Biotherapeutics Inc faces tough competition from several companies in the market. Some of its main competitors include Agenus Inc, Advaxis Inc, and Immune Design Corp. These companies primarily focus on the development and commercialization of novel immunotherapies, similar to Northwest Biotherapeutics Inc. With a similar goal of advancing new treatments, these competitors constantly strive to challenge Northwest Biotherapeutics Inc's market position and contribute to the overall growth and innovation in the field of biopharmaceuticals.

Northwest Biotherapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Northwest Biotherapeutics Inc is focused on developing and commercializing personalized immunotherapy treatments for cancer. The company's approach involves using its proprietary platform technology, known as DCVax®, to target a patient's specific tumor antigens and stimulate the body's immune system to attack and eradicate cancer cells. Northwest Biotherapeutics Inc aims to provide innovative therapies that offer improved clinical outcomes and quality of life for cancer patients.

KGV-d ei saa praegu Northwest Biotherapeutics jaoks arvutada.

KUV-d ei ole võimalik hetkel Northwest Biotherapeutics jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Northwest Biotherapeutics on 7/10.

Praegu ei saa Northwest Biotherapeutics käivet arvutada.

Praegu ei ole võimalik kasumit Northwest Biotherapeutics jaoks arvutada.

Northwest Biotherapeutics Inc is a leading biopharmaceutical company that develops and markets innovative cancer immunotherapies. The company is headquartered in Bethesda, Maryland, USA, and has been listed on the NASDAQ exchange since 1996. The business model of Northwest Biotherapeutics is based on the discovery, development, and commercialization of immunotherapies for a variety of cancer diseases. The company specializes in the development of dendritic cell therapies that aim to stimulate the body's immune system to fight cancer cells. Northwest Biotherapeutics operates multiple business segments, including: 1. Research and Development (R&D) The R&D team of Northwest Biotherapeutics consists of highly qualified scientists and engineers who develop innovative cancer immunotherapies. The company invests significantly in researching and developing new treatments for various types of cancer, including glioblastoma, prostate cancer, and pancreatic cancer. 2. Clinical Trials The company conducts clinical trials worldwide to evaluate the safety and efficacy of its immunotherapies. Northwest Biotherapeutics currently has several ongoing clinical trials treating different types of cancer. The trials are conducted in collaboration with renowned hospitals and medical centers worldwide. 3. Commercial Manufacturing Northwest Biotherapeutics has established a state-of-the-art manufacturing facility that enables the production of dendritic cells on a large scale. The company has the capacity to produce various immunotherapies tailored to the specific needs of patients. 4. Sales and Marketing The company distributes its products through a network of partners and distributors in North America, Europe, and Asia. Northwest Biotherapeutics' sales and marketing team continuously seeks new opportunities to market and distribute its products globally. Northwest Biotherapeutics offers a wide range of immunotherapies to its customers, including DCVax-L and DCVax-Direct. DCVax-L is a personalized vaccine made from the patient's blood and used for the treatment of glioblastoma. DCVax-Direct aims to stimulate the immune response against various types of cancer. In summary, Northwest Biotherapeutics' business model involves developing, manufacturing, and globally marketing innovative cancer immunotherapies. The company invests significantly in R&D and building a sales and marketing network to make its products accessible to a broader customer base. With its unique expertise and innovative products, Northwest Biotherapeutics is well positioned to address future challenges in the field of cancer treatment.

Northwest Biotherapeutics maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Northwest Biotherapeutics jaoks arvutada või ettevõte ei maksa dividende välja.

Northwest Biotherapeutics ISIN on US66737P6007.

Northwest Biotherapeutics WKN on A1J5EY.

Northwest Biotherapeutics tähis on NWBO.

Viimase 12 kuu jooksul maksis Northwest Biotherapeutics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Northwest Biotherapeutics tõenäoliselt dividendi summas 0 USD.

Northwest Biotherapeutics praegune dividenditootlus on .

Northwest Biotherapeutics maksab kvartaalset dividendi. See makstakse välja kuudel .

Northwest Biotherapeutics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Northwest Biotherapeutics on liigitatud sektorisse 'Tervis'.

Viimase Northwest Biotherapeutics dividendide saamiseks 7.9.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 7.9.2024.

Viimane dividendimakse toimus 7.9.2024.

Aastal 2023 maksis Northwest Biotherapeutics 0 USD dividende.

Northwest Biotherapeutics dividendid makstakse välja USD.